SAN ANTONIO, May 31 /PRNewswire-FirstCall/ -- Endocare, Inc. , an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation along with vacuum technologies for erectile dysfunction, announced today that 15 clinical studies and scientific papers related to the Company's cryoablation technology were presented at the 2005 Annual Meeting of the American Urological Association (AUA) held in San Antonio, Texas, May 21-26 at the Henry B. Gonzalez Convention Center.
The data presented spanned the use of cryoablation in four principal areas within urology, including the primary treatment of prostate cancer, the treatment of prostate cancer for those whose cancer has returned following radiation therapy (salvage therapy), the treatment of renal cancer and the focal (or nerve-sparing) treatment of the prostate, a technique aimed at maintaining sexual potency following the procedure.
The accepted abstracts were highlighted by additional 10-year follow-up data using cryoablation to treat prostate cancer in which the study authors concluded that cryosurgery is a safe and effective option for both the primary and salvage treatment of the disease. Also presented were data on salvage cryoablation from studies conducted at UCLA and New York-Columbia Presbyterian Hospital, including 10-year experience with the salvage procedure, and the first abstract ever accepted by the AUA for focal cryoablation. More information including study authors, abstracts and summaries of the data can be accessed via a search engine on the AUA conference website at: http://www.abstractsonline.com/viewer/?mkey={8F546238-4676-48F3-A1A0- ED8D6530F073}.
Endocare Chairman and CEO Craig T. Davenport stated, "The expanded clinical presence of cryoablation at this year's AUA annual meeting is a tribute to the support, enthusiasm, trust and hard work of the many physicians who believe that our technology offers significant advantages for patients. The number of clinical papers presented this year is double that of last year and we anticipate physician awareness and interest will increase due to this increase in clinical studies and papers.
"Another positive indicator of the growing clinical acceptance of cryoablation for prostate and renal cancer treatment coming out of this year's annual meeting is that, for the first time ever, there were formal training courses being led by AUA selected urologists that physicians could attend during the meeting," continued Davenport. "There were four separate courses offered covering cryoablation technology and minimally invasive procedures."
About Endocare
Endocare, Inc. -- www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing devices for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung, liver and bone.
Statements contained in this release that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in "Risk Related to Our Business" in the Company's Forms 10-K, Forms 10-Q, and other filings with the Securities and Exchange Commission. Such risk factors include, but are not limited to, uncertainty relating to ongoing investigations by governmental agencies; changes in and/or attrition to the Company's senior management; uncertainty regarding market acceptance of the Company's products; uncertainty of product development and the associated risks related to clinical trials; uncertainty relating to third party reimbursement; ability to convince health care professionals and third party payers of the medical and economic benefits of the Company's products; difficulty in managing growth; ability to attract and retain key personnel; ability to secure and protect intellectual property rights relating to the Company's technology; the rapid pace of technological change in the Company's industry; fluctuations in the Company's order levels; and the Company's successful relisting on a national stock exchange. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. We undertake no obligation to revise, or update publicly, any forward-looking statements for any reason.
Investor Contact: Matt Clawson Allen & Caron, Inc. (949) 474-4300 matt@allencaron.comwww.allencaron.com Media Contact: Len Hall Allen & Caron, Inc. (949) 474-4300 len@allencaron.com www.allencaron.com For Additional Information: Craig T. Davenport, CEO Michael R. Rodriguez, CFO Endocare, Inc. (949) 450-5400 www.endocare.com
Endocare, Inc.CONTACT: Investors, Matt Clawson, matt@allencaron.com, or Media, Len Hall,len@allencaron.com, both of Allen & Caron, Inc., +1-949-474-4300, forEndocare, Inc.; or Craig T. Davenport, CEO, or Michael R. Rodriguez, CFO,both of Endocare, Inc., +1-949-450-5400
